Anavex Life Sciences Corp (AVXL)

[Anshu2]

Regarding #2, there is a difference between “co-primary” and “multiple primary” endpoints.

For co-primary, the trial is a success if both are met. In this case, p needs to be only less than 0.05. Makes sense.

For multiple primary endpoints, the trial is considered a success if any one of them is met. In this case, p needs to be less than 0.025 for the one met. Makes sense.


Before you refute any of the above by quoting some link etc, please use your own mind too. It doesn’t make sense for p requirement to change for co-primary.

AVXL endpoints were co-primary.